Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results